R01 ES010804/ES/NIEHS NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2003	1
2006	1
2008	2
2009	2
2010	3
2012	2
2016	1
2020	1
2024	0

1

Do caffeine and more selective adenosine A_2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?

Chen JF, Schwarzschild MA. Chen JF, et al. Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1(Suppl 1):S45-S53. doi: 10.1016/j.parkreldis.2020.10.024. Epub 2020 Dec 19. Parkinsonism Relat Disord. 2020. PMID: 33349580 Free PMC article. Review.

2

Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.

Xu K, Di Luca DG, Orrú M, Xu Y, Chen JF, Schwarzschild MA. Xu K, et al. Neuroscience. 2016 May 13;322:129-37. doi: 10.1016/j.neuroscience.2016.02.035. Epub 2016 Feb 22. Neuroscience. 2016. PMID: 26905951 Free PMC article.

3

Incidence of new-onset seizures in mild to moderate Alzheimer disease.

Irizarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, Sano M, Quinn JF, Tariot PN, Galasko DR, Ishihara LS, Weil JG, Aisen PS. Irizarry MC, et al. Arch Neurol. 2012 Mar;69(3):368-72. doi: 10.1001/archneurol.2011.830. Arch Neurol. 2012. PMID: 22410444 Free PMC article.

4

Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease.

Kachroo A, Schwarzschild MA. Kachroo A, et al. Ann Neurol. 2012 Feb;71(2):278-82. doi: 10.1002/ana.22630. Ann Neurol. 2012. PMID: 22367999 Free PMC article.

5

Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration.

Kachroo A, Irizarry MC, Schwarzschild MA. Kachroo A, et al. Exp Neurol. 2010 Jun;223(2):657-61. doi: 10.1016/j.expneurol.2010.02.007. Epub 2010 Feb 24. Exp Neurol. 2010. PMID: 20188092 Free PMC article.

6

Therapeutic directions for Parkinson's disease.

Shoulson I. Shoulson I. Mov Disord. 2010;25 Suppl 1(Suppl 1):S152-4. doi: 10.1002/mds.22790. Mov Disord. 2010. PMID: 20187232 Free PMC article.

7

Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.

Xu K, Xu YH, Chen JF, Schwarzschild MA. Xu K, et al. Neuroscience. 2010 May 5;167(2):475-81. doi: 10.1016/j.neuroscience.2010.02.020. Epub 2010 Feb 16. Neuroscience. 2010. PMID: 20167258 Free PMC article.

8

Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.

Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M. Carta AR, et al. J Neurochem. 2009 Dec;111(6):1478-89. doi: 10.1111/j.1471-4159.2009.06425.x. Epub 2009 Oct 8. J Neurochem. 2009. PMID: 19817968 Free PMC article.

9

Plasma urate and progression of mild cognitive impairment.

Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS. Irizarry MC, et al. Neurodegener Dis. 2009;6(1-2):23-8. doi: 10.1159/000170883. Epub 2008 Nov 5. Neurodegener Dis. 2009. PMID: 19066433 Free PMC article.

10

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.

Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators; Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J. Schwarzschild MA, et al. Arch Neurol. 2008 Jun;65(6):716-23. doi: 10.1001/archneur.2008.65.6.nct70003. Epub 2008 Apr 14. Arch Neurol. 2008. PMID: 18413464 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

12 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year